Aethlon Medical (AEMD) Stock Price, Quote & News

Company Profile

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Industry: Medical Devices

Sector: Healthcare

Phone: 619 941 0360

Fax: 619 941 0361

Website: www.aethlonmedical.com

Address:

11555 Sorrento Valley Road, Suite 203, San Diego, United States

Nuisance May. 20 at 3:47 PM

$AEMD

0 · Reply

pitkineagle May. 20 at 12:32 PM

$AEMD The Expanded Access Protocol for Ebola remains open for patients in Canada and the USA according to the last 10-K.

0 · Reply

Nuisance May. 20 at 11:07 AM

$AEMD 🚀🚀🚀 https://www.prnewswire.com/news-releases/aethlon-medical-announces-approval-of-ebola-treatment-protocol-300014988.html

1 · Reply

SigmaMonark May. 19 at 9:45 PM

$AEMD Diluting.

1 · Reply

stockobserver May. 19 at 8:32 PM

$AEMD They had their chance

1 · Reply

Bank_of_Gotham May. 19 at 7:19 PM

$NA Another 10% today. More than 50% since I called it. So it was right to go in here and not in $AEMD

0 · Reply

YoloAlfred May. 19 at 7:12 PM

$AEMD all uper management added 20,000 shares each

1 · Reply

NotSoEasilyTricked May. 19 at 7:08 PM

$AEMD Administered to individuals infected with Ebola, Sars-CoV-2/Covid, Hepatitis C and HIV To date, Hemopurifier therapy has been administered to individuals infected with Ebola virus, Sars-CoV-2/Covid virus, Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV). In the case of Ebola, a remarkable response to a single administration of Hemopurifier therapy (comatose physician with multiple organ failure at the time), led to Time Magazine in November 2014 naming the Hemopurifier to be one of the "Top 25 Inventions" as well as one of the "Eleven Most Remarkable Advances in Healthcare."

0 · Reply

NotSoEasilyTricked May. 19 at 6:59 PM

$AEMD Thgis company DID cure at least one Ebola patient years ago. The poroduct will never be commercialized because its way to expensive and complex but it DOES work if someone is willing to pay for its use. The management has been run by mostly money blood suckers and insists on doing research for eternity so all investment will be lost in time. However, I'll buy some now, hope for an Ebola pump and then dump the stock hpoing to make back some of what I lost years ago.

0 · Reply

stockobserver May. 19 at 4:28 PM

$AEMD Wonder how many company sold yesterday Big opp missed - they could have pumped it with Ebola pr

0 · Reply

Aethlon Medical Transcript: Emerging Growth Conference 91

Mar 27, 2026, 8:00 AM EDT - 7 weeks ago

Aethlon Medical Slides: Corporate presentation

Mar 24, 2026, 10:30 AM EDT - 2 months ago

Advancements in Novel Immunotherapeutics in The Oncology Battle

2026-03-24T12:11:30.000Z - 2 months ago

Aethlon Medical advances to final cohort in AEMD-2022-06 trial

Mar 24, 2026, 8:01 AM EDT - 2 months ago

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Mar 12, 2026, 1:00 PM EDT - 2 months ago

Aethlon Medical Transcript: Life Sciences Virtual Investor Forum

2026-03-12T12:06:49.000Z - 2 months ago

Aethlon Medical to evaluate range of strategic opportunities

Mar 12, 2026, 8:01 AM EDT - 2 months ago

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Mar 6, 2026, 8:35 AM EST - 2 months ago

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Feb 25, 2026, 12:35 PM EST - 3 months ago

Aethlon Medical Transcript: Emerging Growth Virtual Conference

Feb 23, 2026, 8:01 AM EST - 3 months ago

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Feb 12, 2026, 4:30 PM EST - 3 months ago

Aethlon Medical Earnings Call Transcript: Q3 2026

Feb 12, 2026, 4:30 PM EST - 3 months ago

Aethlon Medical Quarterly report: Q3 2026

Feb 12, 2026, 4:30 PM EST - 3 months ago

Aethlon Medical Earnings release: Q3 2026

2026-02-12T21:22:12.000Z - 3 months ago

Aethlon Medical reports Q3 EPS ($2.45) vs. ($10.05) last year

Feb 12, 2026, 4:15 PM EST - 3 months ago

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Feb 4, 2026, 8:01 AM EST - 3 months ago

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

Jan 27, 2026, 7:00 AM EST - 4 months ago

Aethlon Medical Proxy statement: Proxy Filing

Jan 16, 2026, 7:00 AM EST - 4 months ago

Aethlon Medical Proxy statement: Proxy Filing

2026-01-07T21:21:45.000Z - 4 months ago

Aethlon Medical files to sell 2.03M shares of common stock for holders

Jan 7, 2026, 7:00 AM EST - 4 months ago

Aethlon Medical Registration statement: Registration Filing

2025-12-23T20:10:15.000Z - 5 months ago

Aethlon Medical files to sell $15M of common stock

Dec 23, 2025, 7:00 AM EST - 5 months ago

Aethlon Medical Registration statement: Registration Filing

2025-12-05T14:20:35.000Z - 5 months ago

Aethlon Medical announces $3.3M private placement

Dec 5, 2025, 9:15 AM EST - 5 months ago

Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

2025-12-02T13:10:50.000Z - 6 months ago

Aethlon Medical’s Hemopurifier shows potential efficacy in long COVID

Dec 2, 2025, 8:01 AM EST - 6 months ago

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs

Nov 12, 2025, 4:30 PM EST - 6 months ago

Aethlon Medical Earnings Call Transcript: Q2 2026

Nov 12, 2025, 4:30 PM EST - 6 months ago

Aethlon Medical Quarterly report: Q2 2026

Nov 12, 2025, 4:30 PM EST - 6 months ago

Aethlon Medical Earnings release: Q2 2026

2025-11-12T21:26:43.000Z - 6 months ago

Aethlon Medical reports Q2 EPS ($3.74) vs. ($16.11) last year

Nov 12, 2025, 4:15 PM EST - 6 months ago

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

Nov 7, 2025, 8:01 AM EST - 6 months ago

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

2025-10-17T23:50:14.000Z - 7 months ago

Aethlon Medical trading halted, news pending

Oct 7, 2025, 8:01 AM EDT - 8 months ago

Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial

2025-09-04T13:25:35.000Z - 9 months ago

Aethlon Medical announces pricing of $4.5M common stock, warrant offering

Sep 4, 2025, 9:15 AM EDT - 9 months ago

Aethlon Medical Announces Pricing of $4.5 Million Public Offering

2025-09-03T12:11:26.000Z - 9 months ago

Aethlon Medical announces issuance of patents protecting Hemopurifier

Sep 3, 2025, 8:01 AM EDT - 9 months ago

Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)

Aug 29, 2025, 8:00 AM EDT - 9 months ago

Aethlon Medical Registration statement: Registration Filing

2025-08-21T23:54:00.000Z - 9 months ago

Why Is Aethlon Medical Stock (AEMD) Up 60% Today?

2025-08-20T21:25:09.000Z - 9 months ago

Aethlon Medical files to sell common stock, warrants, no amount given

Aug 20, 2025, 8:00 AM EDT - 9 months ago

Aethlon Medical Registration statement: Registration Filing

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Aethlon Medical Earnings Call Transcript: Q1 2026

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Aethlon Medical Quarterly report: Q1 2026

Aug 13, 2025, 4:30 PM EDT - 10 months ago

Aethlon Medical Earnings release: Q1 2026

2025-08-13T20:20:55.000Z - 10 months ago

Aethlon Medical reports Q1 EPS (85c) vs. ($2.76) last year

Aug 13, 2025, 4:15 PM EDT - 10 months ago

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update

Aug 5, 2025, 8:01 AM EDT - 10 months ago

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025

Jul 15, 2025, 8:01 AM EDT - 11 months ago

Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort

2025-07-07T10:10:42.000Z - 11 months ago

Aethlon Medical assumed with a Neutral at H.C. Wainwright

2025-06-27T12:35:09.000Z - 11 months ago

Aethlon Medical reports FY25 EPS ($8.58) vs. ($38.87) last year

Jun 26, 2025, 4:30 PM EDT - 11 months ago

Aethlon Medical Earnings Call Transcript: Q4 2025

Jun 26, 2025, 4:30 PM EDT - 11 months ago

Aethlon Medical Annual report: Q4 2025

Jun 26, 2025, 4:30 PM EDT - 11 months ago

Aethlon Medical Earnings release: Q4 2025

Jun 26, 2025, 4:15 PM EDT - 11 months ago

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update

Jun 20, 2025, 8:01 AM EDT - 11 months ago

Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025

Jun 18, 2025, 8:01 AM EDT - 1 year ago

Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial

Jun 17, 2025, 3:40 PM EDT - 1 year ago

Aethlon Medical Transcript: Emerging Growth Conference 83

Jun 9, 2025, 8:01 AM EDT - 1 year ago

Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes

May 14, 2025, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Aethlon Medical Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Aethlon Medical Proxy statement: Proxy Filing

Mar 26, 2025, 3:25 PM EDT - 1 year ago

Aethlon Medical Transcript: Emerging Growth Virtual Conference

Mar 10, 2025, 8:01 AM EDT - 1 year ago

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Feb 19, 2025, 11:25 AM EST - 1 year ago

Aethlon Medical Transcript: Emerging Growth Conference 79

Feb 13, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025

Feb 12, 2025, 4:30 PM EST - 1 year ago

Aethlon Medical Earnings Call Transcript: Q3 2025

Feb 12, 2025, 4:30 PM EST - 1 year ago

Aethlon Medical Quarterly report: Q3 2025

Feb 12, 2025, 4:30 PM EST - 1 year ago

Aethlon Medical Earnings release: Q3 2025

Feb 12, 2025, 4:15 PM EST - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

Feb 5, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

Jan 29, 2025, 8:01 AM EST - 1 year ago

Aethlon Medical Treats First Patient in Australian Hemopurifier® Cancer Trial

Dec 20, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

Nov 14, 2024, 8:00 AM EST - 1 year ago

Biotech and Medical Tech Stocks Report Significant Updates in the Race for Cancer Treatments as Cancer Rates Rise Globally

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aethlon Medical Earnings Call Transcript: Q2 2025

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aethlon Medical Quarterly report: Q2 2025

Nov 13, 2024, 4:30 PM EST - 1 year ago

Aethlon Medical Earnings release: Q2 2025

Nov 13, 2024, 4:15 PM EST - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

Nov 12, 2024, 8:00 AM EST - 1 year ago

Innovative Medical Technology Advances with First Patient Enrollments

Nov 11, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia

Nov 6, 2024, 8:01 AM EST - 1 year ago

Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024

Oct 15, 2024, 4:30 PM EDT - 1 year ago

Aethlon Medical Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 8, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Sep 19, 2024, 8:01 AM EDT - 1 year ago

Aethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in India

Sep 17, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical to Present at Virtual Investor Conferences in September

Sep 17, 2024, 7:30 AM EDT - 1 year ago

Innovation Driving Cancer's Solid Tumors Market

Sep 16, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial

Sep 13, 2024, 8:35 AM EDT - 1 year ago

Aethlon Medical to Present at the Life Sciences Investor Forum September 19th

Aug 27, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Aethlon Medical Proxy statement: Proxy Filing

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Aethlon Medical Proxy statement: Proxy Filing

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Aethlon Medical Earnings Call Transcript: Q1 2025

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Aethlon Medical Quarterly report: Q1 2025

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Aethlon Medical Earnings release: Q1 2025

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update

Aug 12, 2024, 9:01 AM EDT - 1 year ago

The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

Aug 12, 2024, 8:01 AM EDT - 1 year ago

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial

Aug 6, 2024, 9:12 AM EDT - 1 year ago

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024

Jun 27, 2024, 4:30 PM EDT - 2 years ago

Aethlon Medical Earnings Call Transcript: Q4 2024

Jun 27, 2024, 4:30 PM EDT - 2 years ago

Aethlon Medical Annual report: Q4 2024

Jun 27, 2024, 4:30 PM EDT - 2 years ago

Aethlon Medical Earnings release: Q4 2024

Jun 27, 2024, 4:15 PM EDT - 2 years ago

Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Jun 21, 2024, 8:01 AM EDT - 2 years ago

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024

Jun 20, 2024, 7:00 AM EDT - 2 years ago

What's Next in Treatments for Cancer Patients with Solid Tumors?

Jun 18, 2024, 8:01 AM EDT - 2 years ago

Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Jun 7, 2024, 8:00 AM EDT - 2 years ago

The Hunt for Virus Treatments Continues Post Covid-19

Nuisance May. 20 at 3:47 PM

$AEMD

0 · Reply

pitkineagle May. 20 at 12:32 PM

$AEMD The Expanded Access Protocol for Ebola remains open for patients in Canada and the USA according to the last 10-K.

0 · Reply

Nuisance May. 20 at 11:07 AM

$AEMD 🚀🚀🚀 https://www.prnewswire.com/news-releases/aethlon-medical-announces-approval-of-ebola-treatment-protocol-300014988.html

1 · Reply

SigmaMonark May. 19 at 9:45 PM

$AEMD Diluting.

1 · Reply

stockobserver May. 19 at 8:32 PM

$AEMD They had their chance

1 · Reply

Bank_of_Gotham May. 19 at 7:19 PM

$NA Another 10% today. More than 50% since I called it. So it was right to go in here and not in $AEMD

0 · Reply

YoloAlfred May. 19 at 7:12 PM

$AEMD all uper management added 20,000 shares each

1 · Reply

NotSoEasilyTricked May. 19 at 7:08 PM

0 · Reply

NotSoEasilyTricked May. 19 at 6:59 PM

0 · Reply

stockobserver May. 19 at 4:28 PM

$AEMD Wonder how many company sold yesterday Big opp missed - they could have pumped it with Ebola pr

0 · Reply

Max_Relativity May. 19 at 3:19 PM

$AEMD I still like it.

0 · Reply

YoloAlfred May. 19 at 3:11 PM

$AEMD AH super ripper

0 · Reply

YoloAlfred May. 19 at 3:11 PM

$AEMD $CODX real tradable float for $AEMD is 159,877 shares...yes that tiny...add it up for yourself

0 · Reply

YoloAlfred May. 19 at 3:08 PM

$AEMD it could with the right contract or PR....Hit $50+ with less than 200k available to trade

0 · Reply

YoloAlfred May. 19 at 3:07 PM

$AEMD only 159,877 shares available to trade..1.6 million minus 1,440,123 held by institutions

0 · Reply

YoloAlfred May. 19 at 1:59 PM

$AEMD 5x-10x soon

0 · Reply

YoloAlfred May. 19 at 1:56 PM

$AEMD loading more

0 · Reply

YoloAlfred May. 19 at 1:43 PM

$AEMD going to sit on my shares....and just wait....its going to explode

0 · Reply

YoloAlfred May. 19 at 1:39 PM

$AEMD Steven Boyd added 82,410 shares

0 · Reply

YoloAlfred May. 19 at 1:12 PM

$AEMD One PR for the Aethlon Hemopurifier to treat Ebola....and boom 10X

0 · Reply

stockobserver May. 19 at 1:10 PM

$AEMD Company has opportunity to do an Ebola pump

0 · Reply

YoloAlfred May. 19 at 1:10 PM

$AEMD added...

0 · Reply

Market Cap	3.22M
Revenue (ttm)	0.00
Net Income (ttm)	-13.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	39,400
Avg Vol	68,328
Day's Range	N/A - N/A
Shares Out	1.57M
Stochastic %K	18%
Beta	1.50
Analysts	Hold
Price Target	$4.75